ArchivesMagazine - 16 Aug 2018Will Turkey-led emerging markets sell-off hurt Mobius’ plan for new trust? Most trusts in this space are already trading at discounts to net asset value 16 August 2018|Investment Trusts|by Tom Sieber Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email < Failing life expectancy growth could boost pension providers’ dividends What is free cash flow and why is it so important? > Issue: 16 Aug 2018 - Page 38 | Contents Next: What is free cash flow and why is it so important? Previous: Failing life expectancy growth could boost pension providers’ dividends Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email Tom Sieber Issue Contents Editor's View Why hasn’t gold rallied on the Turkish crisis? Education What is free cash flow and why is it so important? Feature Failing life expectancy growth could boost pension providers’ dividends Up, up and away: 8 momentum stocks to buy now Funds The lowdown on thematic ETFs Great Ideas Load up on Sabre Insurance for juicy dividends with potential 7.8% yield International Biotechnology Trust set to benefit from population growth Volution blown down by factory-related headwinds 2018 shaping up nicely for fast growing SciSys DP Eurasia out in the cold due to currency crash Why you can relax on RELX Investment Trusts The ultimate income investment trusts BlackRock Throgmorton adopts the Whitestone way Will Turkey-led emerging markets sell-off hurt Mobius’ plan for new trust? News Why the collapse in Turkish lira matters to investors Esure snapped up by Bain Capital Electric vehicles boost for auto-engineer TI Fluid Sensyne Health floats on AIM with plan to speed up drug discovery via NHS partnership More in the tank for TT Electronics as it scales value chain Personal Finance What rising interest rates could mean for your pension Russ Mould Three reasons why the FTSE 100 can make a fresh high before year-end (and three why it may not) Under The Bonnet AstraZeneca sets sights on return to sales growth despite potential Brexit troubles
